Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19*

Both authors: Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE *See also p. 337. Dr. Cawcutt received funding from Becton, Dickinson and Company. Dr. Kalil has disclosed that he was an investigator for the National Institutes of Health Adaptive COVID-19 Treatment Trial.